Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01332266 · ClinicalTrials.gov registry record · Phase 1
E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
A Phase 1 study of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck, sponsored by Eisai.
- Completed
- Registry status
- Phase 1
- Development phase
- 95
- Enrollment target
- 20
- Study locations
NCT01332266 is a Phase 1 study of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck that has completed, run by Eisai. The registered enrollment target is 95 participants. The trial reports 20 study locations across 10 states.
The verdict
NCT01332266, a Phase 1 study of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 95 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether participants with platinum-resistant squamous cell carcinoma of the head and neck (SCCHN) who receive either E7050 administered with cetuximab or cetuximab alone experience greater benefit.
Conditions Studied
Interventions
- DRUG Cetuximab
- DRUG E7050
Study Locations (20)
Other
- - Busan
- - Seoul
- - Seoul
- - Seoul
- - Seoul
- - Dnipropetrovsk
- - Donetsk
- - Donetsk
- - Kharkiv
- - Kyiv
- - Sumy
Arizona
- - Tucson
Florida
- - Fort Myers
Massachusetts
- - Boston
Missouri
- - St Louis
Ohio
- - Toledo
Oklahoma
- - Oklahoma City
Tennessee
- - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2011-09-19 |
| Est. Completion | 2017-09-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01332266
The ClinicalTrials.gov registry entry for NCT01332266 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck appearing as the primary indexed condition, and to 2 interventions - of which Cetuximab is the first listed.
NCT01332266 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT01332266 about?
NCT01332266 is a clinical study titled "E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck". The purpose of this study is to determine whether participants with platinum-resistant squamous cell carcinoma of the head and neck (SCCHN) who receive either E7050 administered with cetuximab or cetuximab alone experience greater benefit.
What is the current status of trial NCT01332266?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 95 participants. The study started on 2011-09-19. Estimated completion is 2017-09-04.
What conditions does trial NCT01332266 study?
This clinical trial studies the following conditions: Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck.
What interventions are being tested in trial NCT01332266?
The interventions under investigation include: Cetuximab (DRUG), E7050 (DRUG).
Who is sponsoring clinical trial NCT01332266?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01332266 being conducted?
This trial has 20 study locations across Arizona, Florida, Massachusetts, Missouri, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.